{"preliminary_commentary":{"by_channel":{"x_thread":10,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05276609\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["risvutatug rezetecan (HS-20093)"]],"indication":"locally advanced or metastatic solid tumors","name":"ARTEMIS-001","nct_id":"NCT05276609","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=artemis-001-nct05276609. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"There are seven escalating dose cohorts.","label":"HS-20093 (Phase Ia: Dose escalation)","type":"EXPERIMENTAL"},{"description":"The recommended dose from the dose-escalation stage and other potential doses will be further explored.","label":"HS-20093 (Phase Ib: Dose expansion)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2023-12-31","type":"ESTIMATED"},"conditions":["Advanced Solid Tumor"],"enrollment":{"count":177,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"HS-20093 (Phase Ia: Dose escalation)","otherNames":[],"type":"DRUG"},{"name":"HS-20093 (Phase Ib: Dose expansion)","otherNames":[],"type":"DRUG"}],"last_update":"2023-02-15","lead_sponsor":"Shanghai Hansoh Biomedical Co., Ltd","official_title":"ARTEMIS-001: A Phase 1, Open-label, Multi-center Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Multiple Doses of Intravenous Administration of HS-20093 in Patients With Locally Advanced or Metastatic Solid Tumors Who Have Progressed Following Prior Therapy","overall_status":"UNKNOWN","phases":["PHASE1"],"primary_completion_date":{"date":"2023-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Ⅰa (Dose-Escalation Stage): Maximum tolerated dose (MTD) for HS-20093","timeFrame":"Up to day 21 from the first dose"},{"measure":"Ⅰb (Dose-Expansion Stage): Objective response rate (ORR) determined by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1","timeFrame":"From the first dose up to PD or withdrawal from study, whichever came first, assessed up to 24 months"}],"references":[],"start_date":{"date":"2021-11-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT05276609"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/artemis-001-nct05276609"}